GENE EXPRESSION PROFILES IN HEPARG CELLS TO DISCRIMINATE GENOTOXIC FROM NON GENOTOXIC COMPOUNDS

D. GIRET¹, A. HUGUET¹, S. CAMUS², N. ROUGIER², C. CHESNE², V. FESSARD¹ and L. LE HEGARAT¹

¹French Agency for Food, Environmental and Occupational Health & Safety, Toxicology of contaminants Unit, Fougeres, France. Contact: ludovic.lehegarat@anses.fr. ²Biopredic International, Rennes, France

Background

Because of metabolic bioactivation plays a major role in the genotoxic response of environmental human carcinogens, genotoxicity assays are performed with induced rat liver S9 fraction to mimic the liver metabolism. However, extrapolating of results from the metabolism rodent to humans is questionable. Among the human cell culture models mimicking human liver metabolism, the hepatoma HepaRG cells are certainly one of the most promising in vitro model for genetic toxicology. They express most of liver-specific functions (phase I and II enzymes, nuclear receptors, ...). In order to determine if the cryopreserved HepaRG model is suitable for detecting genotoxic carcinogens, we conducted an study to characterize gene expression signatures of exposure to 4 genotoxic compounds (GTX) (AflatoxinB1, MMS, 4-NNO and cyclophosphamide) and 4 non genotoxic compounds (NGTX) (D-mannitol, EDTA, DHEP, methylcarbamate). Principal component analysis (PCA) was applied to identify data patterns and highlight data differences between GTX and NGTX compounds. This study demonstrated the suitability of the HepaRG cell model for mutagenesis evaluation based on gene expression alterations.

Results

RT-QPCR in HepaRG cells treated with GTX and NGTX

Gene expression analysis

Frozen differentiated HepaRG cells in suspension

Seeding at high density 200’000 cells/cm²

One week later, highly differentiated cells

Table 1: list of genes used in this study

<table>
<thead>
<tr>
<th>Gene</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCDUA</td>
<td>ATP citrate shuttle protein</td>
</tr>
<tr>
<td>MSH2</td>
<td>MutS homolog 2</td>
</tr>
<tr>
<td>BTG2</td>
<td>BTG tumor suppressor family</td>
</tr>
<tr>
<td>TP73</td>
<td>Tumor protein 73</td>
</tr>
<tr>
<td>EPHA1</td>
<td>Epidermal growth factor receptor 1</td>
</tr>
<tr>
<td>DHEP</td>
<td>Dihydrolipoamide S-transferase</td>
</tr>
<tr>
<td>MMS</td>
<td>Methyl methanesulfonate</td>
</tr>
<tr>
<td>CPA</td>
<td>Chloroethyl acetamide</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>4-NNO</td>
<td>1,2-dimethylhydrazine</td>
</tr>
</tbody>
</table>

Expression of 10 target genes was assessed in response to GTX and NGTX compounds in HepaRG cells. We found that 7 genes (CDKN1A, MSH2, BTG2, TP73, FAS, EPHX1 and GADD45γ) showed similarity expression profiles that permit the discrimination between GTX and NGTX compounds. GTX compounds induced overexpression of CDKN1, MSH2, BTG2, TP73 and FAS genes and underexpression of GADD45γ and EPHX1.

Conclusion

These results showed that gene expression profiles of HepaRG cells could distinguish genotoxic from non-genotoxic compounds. Among the GTX compounds (MMS, 4-NNO, AFB1 and CPA) only CPA which was showed to induce DNA damage in HepaRG cells, failed to be distinguished from NGTX compounds (EDTA, Mannitol, DHEP and Methylcarbamate).

Then, the combining the used of a human metabolic competent cell line like differentiated HepaRG cells and gene expression profiling may become a suitable method to identify human genotoxic carcinogens.

Principal component analysis (PCA) was applied to identify data patterns and to highlight data similarity and difference between the GTX and NGTX treated HepaRG cells. PCA of all 10 genes was unable to discriminate the GTX from the NGTX compounds. However, selecting 4 specific genes (FAS, MSH2, EPHX1, GADD45γ), enables an optimal separation between the two types of compounds. We found that Methylcarbamate, DHEP, EDTA and DMSO exhibited a first principal component and MMS, AFB1 and 4-NNO a second principal component. However, CPA could not be distinguished from the NGTX compounds.